Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting

被引:17
作者
Hallinen, T.
Martikainen, J. A.
Soini, E. J. O.
Suominen, L.
Aronkyto, T.
机构
[1] Univ Kuopio, Dept Social Pharm, Ctr Pharmaceut Policy & Econ, FI-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Hlth Policy & Management, FI-70211 Kuopio, Finland
[3] Espoo Ctr Social & Hlth Serv, Espoo, Finland
[4] Ctr Hlth, Helsinki, Finland
关键词
atrial fibrillation; cost analysis; costs; warfarin;
D O I
10.1185/030079906X100014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The main objective was to estimate the mean direct costs of warfarin treatment for atrial fibrillation (AF) patients. Secondly, the costs of initiating warfarin treatment during a 60-day period and the impact of International Normalized Ratio (INR) and co-morbidities on costs were estimated. Design and data: The study was performed as a retrospective cohort study over a 12-month period in a Finnish communal health care setting. All AF patients aged 65 years or older (n = 250) with warfarin treatment were identified from the database of the health service district of an urban area. Patient specific information related to comorbidities, INR-control, complications and health care resource use were collected. Cost information was obtained from the Finnish national health care unit cost list. Methods: The effect of treatment balance and other background variables on treatment costs were evaluated using ordinary least squares regression (OLS), log-transformed OLS and generalized linear model (GLM). The mean costs were calculated on the basis of the different models and bias corrected and accelerated (BCa) bootstrap confidence intervals (Cis) were calculated for the mean costs. Results: The best fitting cost model was log-transformed OLS. The costs of warfarin treatment on the basis of the log-transformed model were 589.82 euros (BCa. 95% CI: 586.68-591.99) per patient compared to 616.00 euros (BCa 95% CI: 579.98-652.96) obtained with the OLS-model. For the treatment initiation period, the mean costs were 263 euros (BCa 95% CI: 218.9G-314.71). Depending on the way that INR-control was defined, the mean costs were 95.27 euros or 166.92 euros higher for patients who were not in the defined INR-balance. Conclusions: The INR-control has a significant impact on the warfarin treatment costs. The choice of model influences the estimated mean costs. In addition, different models identify statistically significant effects between different background variables and costs.
引用
收藏
页码:683 / 692
页数:10
相关论文
共 20 条
  • [1] Abdelhafiz Ahmed H, 2003, Am J Geriatr Pharmacother, V1, P53, DOI 10.1016/S1543-5946(03)90001-8
  • [2] Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
    Aguilar, M.
    Hart, R.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (04):
  • [3] Anderson Robert J, 2004, J Manag Care Pharm, V10, P159
  • [4] [Anonymous], 2005, Stata Statistical Software: Release 9
  • [5] Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249
  • [6] Multimodel inference - understanding AIC and BIC in model selection
    Burnham, KP
    Anderson, DR
    [J]. SOCIOLOGICAL METHODS & RESEARCH, 2004, 33 (02) : 261 - 304
  • [7] Atrial fibrillation in the elderly - Facts and management
    Chatap, G
    Giraud, K
    Vincent, JP
    [J]. DRUGS & AGING, 2002, 19 (11) : 819 - 846
  • [8] *COLL STAT, 2005, STAT BAS REF MAN, V2
  • [9] DRUMMOND M, 2001, STAT CONSIDERATIONS